33 / 48
LORLATINIB
Efficacy in EXP4 (ALK
+
, 2 ALK TKIs
±
CT)
and EXP5 (ALK
+
, ≥3 ALK TKIs
±
CT)
70
60
10
0
30
20
50
40
‒10
‒20
‒30
‒40
‒50
‒60
‒70
‒80
‒90
‒100
70
60
10
0
30
20
50
40
‒10
‒20
‒30
‒40
‒50
‒60
‒70
‒80
‒90
‒100
Best Change From Baseline (%)
EXP4+5 (n=111)
ORR, n/N (%)
(95% CI)
43/111 (39)
(30, 49)
IC ORR, n/N (%)
(95% CI)
40/83 (48)
(37, 59)
Median DOR, mo (95%
CI)
NR
(5.5, NR)
DOR ≥6 mo, n⁰/n (%)
20/43 (47)
Median PFS, mo
(95% CI)
6.9
(5.4, 9.5)
• 83 patients (75%) had brain
metastases at baseline.
Overall
Intracranial
Off treatment or PD occurred
Complete response
Partial response
Stable disease
Progressive disease (PD)
Indeterminate
CI, confidence interval; CT, chemotherapy; DOR, duration of response; mo, months; NR, not reached.
Solomon et al, WCLC 2017
Shaw A, et al. Lancet Oncol 2017